...
首页> 外文期刊>Journal of Surgical Oncology >Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma
【24h】

Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma

机译:合并肝细胞癌-胆管癌患者的移植与切除

获取原文
获取原文并翻译 | 示例

摘要

Background and Objectives Although transplantation has demonstrated survival benefit for patients with hepatocellular carcinoma (HCC), there is limited data to support or refute transplantation for combined hepatocellular-cholangiocarcinoma (cHCC-CC). We hypothesized that cHCC-CC patients had poorer overall survival (OS) than HCC patients after liver transplantation. Methods Patients with localized HCC and cHCC-CC treated with surgical resection or transplant were identified using the Surveillance, Epidemiology, and End Results (SEER) Database (1973-2007). Cox proportional hazards models were used to examine survival. Results We identified 3,378 (1,447 [43%] transplant, 1,931 [57%] resection) patients with HCC, and 54 (19 [35%] transplant, 35 [65%] resection) patients with cHCC-CC. Patients undergoing resection of HCC and cHCC-CC had similar 3-year OS (55% vs. 46%, P = 0.4). Three-year OS of patients undergoing transplant was significantly greater for HCC (78%) than for cHCC-CC (48%, P = 0.01). In adjusted models, patients transplanted for cHCC-CC had higher hazard of death compared to HCC patients (HR 2.5, 95% CI: 1.2-5.1, P = 0.01). Conclusions Transplantation for localized cHCC-CC confers a survival benefit similar to liver resection for cHCC-CC, but inferior to transplantation for HCC. With survival data that mimics historic reports of transplant for intrahepatic cholangiocarcinoma, this study questions the benefit of transplantation for patients with cHCC-CC.
机译:背景与目的尽管移植已证明对肝细胞癌(HCC)患者具有生存益处,但仅有有限的数据支持或驳斥合并肝细胞胆管癌(cHCC-CC)的移植。我们假设肝移植后cHCC-CC患者的总生存期(OS)比HCC患者差。方法使用监测,流行病学和最终结果(SEER)数据库(1973-2007),对接受手术切除或移植的局部HCC和cHCC-CC患者进行鉴定。考克斯比例风险模型用于检查生存率。结果我们确定了3378例HCC患者(1,447例[43%]移植,1931例[57%]切除)和54例cHCC-CC病例(19例[35%]移植35例[65%]切除)。接受HCC和cHCC-CC切除的患者的3年OS相似(55%比46%,P = 0.4)。接受肝移植的患者三年OS显着高于cHCC-CC(48%,P = 0.01)(78%)。在调整后的模型中,移植了cHCC-CC的患者比HCC患者具有更高的死亡危险(HR 2.5,95%CI:1.2-5.1,P = 0.01)。结论局限性cHCC-CC的移植与cHCC-CC的肝切除具有相似的生存获益,但劣于HCC的移植。利用能够模拟肝内胆管癌移植历史报道的生存数据,这项研究对移植对于cHCC-CC患者的益处提出了质疑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号